News
After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback